Incyte and MorphoSys AG announced that the European Medicines Agency's Committee for Medicinal Products for Human Use (CHMP) has issued a positive opinion recommending the conditional marketing authorization of tafasitamab in combination with lenalidomide, followed by tafasitamab monotherapy, for the treatment of adult patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL) who are not eligible for autologous stem cell transplantation (ASCT).
Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
67.78 EUR | +0.04% | +0.07% | +99.26% |
Apr. 11 | Health Care Slips on Risk Bias -- Health Care Roundup | DJ |
Apr. 11 | Trending : Novartis Begins Tender Offer for MorphoSys Shares | DJ |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
+99.26% | 2.73B | |
+1.12% | 42.59B | |
+6.77% | 40.65B | |
+47.02% | 40.57B | |
-11.96% | 26.77B | |
+6.01% | 24.81B | |
-24.92% | 18.17B | |
-3.63% | 11.7B | |
+27.16% | 12.05B | |
+7.30% | 11.1B |
- Stock Market
- Equities
- MOR Stock
- News MorphoSys AG
- Incyte and MorphoSys Announce Positive CHMP Opinion for Tafasitamab in Combination with Lenalidomide for the Treatment of Adults with Relapsed or Refractory Diffuse Large B-Cell Lymphoma